Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir in Virologically-suppressed HIV-infected Rwandans (Near-Rwanda)'

Trial Profile

Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir in Virologically-suppressed HIV-infected Rwandans (Near-Rwanda)'

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms Near Rwanda
  • Most Recent Events

    • 20 Jul 2015 Status changed from not yet recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 15 Jul 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as per ClinicalTrials.gov record.
    • 29 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top